^
Association details:
| Biomarker: | EGFR wild-type + ALK wild-type |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | izalontamab (SI-B001) (EGFR inhibitor, HER3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.
Excerpt:
...Patients with locally advanced or metastatic EGFR wild-type ALK wild-type lung cancer, disease progression or intolerance after first-line treatment with anti-PD-1/PD-L1 antibody, disease progression or intolerance after first-line treatment with anti-PD-1/PD-L1 antibody and platinum-based chemotherapy, or progression or intolerance after first-line treatment with anti-PD-1/PD-L1 monoclonal antibody; 6....
Trial ID:
Source:
Title:
SI-B001 plus chemotherapy in patients with locally advanced or metastatic EGFR/ALK wild-type non-small cell lung cancer: A phase II, multicenter, open-label study.
Published date:
05/25/2023
Excerpt:
This phase II study enrolled patients with locally advanced or metastatic EGFR/ALK wild-type NSCLC who had failed first-line anti-PD-1/L1 therapy, with or without platinum-based chemotherapy...Among 22 evaluable pts in schedule 1 the ORR was 45.5% (10/22, [24.5, 67.8]) and the DCR was 68.2% (15/22, [45.1, 86.1])....SI-B001 plus docetaxel demonstrated antitumor activity in locally advanced or metastatic NSCLC EGFR/ALK wild-type pts who failed on prior first-line anti-PD-1/L1 antibody plus PBC, especially without AGA.
DOI:
10.1200/JCO.2023.41.16_suppl.9025
Trial ID: